Intangible Assets

No filing-based evidence provided of patents, proprietary formulations, or regulatory exclusivity, so ZENA appears to lack durable IP that would let it sustain pricing power versus peers.

The absence of disclosed long-run margin or ROIC history, combined with deeply negative TTM ROIC, suggests any brand or know-how advantage is not translating into peer-leading economics.

Without evidence of protected clinical, manufacturing, or data assets, competitors can likely replicate the offering, which keeps intangible assets below most durable peer moats.

Switching Costs

The provided metrics do not show retention, contract lock-in, or workflow integration, so customers appear able to switch with limited economic friction versus peers.

Negative ROIC and ROCE indicate the company is not yet monetizing any embedded customer dependence, which weakens the case for durable switching costs.

Compared with peers that benefit from regulated, recurring, or system-integrated demand, ZENA shows no evidence of comparable stickiness.

Network Effects

No evidence is provided of a user, data, or ecosystem flywheel, so ZENA does not appear to benefit from self-reinforcing adoption versus peers.

The negative capital returns imply scale is not compounding into stronger platform utility, which is inconsistent with meaningful network effects.

Relative to peers with multi-sided platforms or data advantages, ZENA shows no disclosed mechanism that would make each additional customer more valuable to the next.

Cost Advantage

TTM ROIC of -44.1% and ROCE of -46.2% indicate the business is not currently converting capital into superior unit economics, which argues against a cost edge versus peers.

Asset turnover of 0.19 suggests low asset productivity, so ZENA does not appear to have a structural operating-cost advantage that would support durable margins.

In the absence of disclosed scale purchasing, manufacturing, or logistics advantages, peers likely have at least comparable or better cost positions.

Efficient Scale

The available data do not show a natural-monopoly or capacity-constrained market structure, so ZENA does not appear to operate in an efficient-scale niche versus peers.

Negative returns on capital imply the company is not yet earning excess profits from limited market size or incumbent protection, which weakens efficient-scale durability.

Compared with peers in regulated or highly concentrated markets, ZENA shows no evidence that market size alone protects it from competitive entry.

Overall Score

ZENA shows no disclosed evidence of durable moat drivers, and the deeply negative TTM ROIC/ROCE plus weak asset productivity suggest it is not currently sustaining pricing power, retention, or superior economics versus peers.